ADMA Biologics Inc (NASDAQ:ADMA) reported Q2 2017 earnings this N/A, coming in at ($0.55) per share, missing Wall Street’s estimates of ($0.26) per Share. Revenue for the quarter came in at $3.40 million missing the streets estimates of $3.52 million
Analyst Coverage For ADMA Biologics Inc (NASDAQ:ADMA)
These are 1 Buy Rating .
The current consensus rating for ADMA Biologics Inc (NASDAQ:ADMA) is Buy (Score: 3.00) with a consensus target price of $13.00 , a potential (342.18% upside)Recent Insider Trading for ADMA Biologics Inc (NASDAQ:ADMA)
- On 5/3/2016 Adam S Grossman, CEO, bought 200,000 with an average share price of $6.50 per share and the total transaction amounting to $1,300,000.00.
- On 5/3/2016 Brian Lenz, CFO, bought 2,500 with an average share price of $6.50 per share and the total transaction amounting to $16,250.00.
- On 5/3/2016 James Mond, CMO, bought 770 with an average share price of $6.50 per share and the total transaction amounting to $5,005.00.
- On 5/3/2016 Jerrold B Grossman, Director, bought 45,769 with an average share price of $6.50 per share and the total transaction amounting to $297,498.50.
- On 12/8/2015 Adam S. Grossman, CEO, bought 500 with an average share price of $9.00 per share and the total transaction amounting to $4,500.00.
- On 12/7/2015 Jerrold B Grossman, Director, bought 500 with an average share price of $9.01 per share and the total transaction amounting to $4,505.00.
Recent Trading for ADMA Biologics Inc (NASDAQ:ADMA) Shares of ADMA Biologics Inc closed the previous trading session at 2.94 up +0.03 1.03% with 36,784 shares trading hands.